Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Merck & Co Inc (NYSE:MRK)

57.61
Delayed Data
As of 4:01pm ET
 +0.56 / +0.98%
Today’s Change
45.69
Today|||52-Week Range
60.07
+9.07%
Year-to-Date
Eli Lilly Stock Up on FDA Advisory Panel Vote for Jardiance
10:29am / Zacks.com - Paid Partner Content
Zika vaccine maker's stock is on fire
Jun 22 / CNNMoney.com
How J&J Defied Brexit and Became the Year's Top Health Care Stock
Jun 29 / TheStreet.com - Paid Partner Content
Stock Market News for June 20, 2016
Jun 20 / Zacks.com - Paid Partner Content
How Pfizer, Merck May Feel Long-term Pinch From Brexit
Jun 29 / TheStreet.com - Paid Partner Content
The Zacks Analyst Blog Highlights: Baker Hughes, LinkedIn, Microsoft, Apple and Merck
Jun 20 / Zacks.com - Paid Partner Content
The FDA Unsurprisingly Approves Gilead's New Hepatitis C Drug. Now What?
Jun 28 / MotleyFool.com - Paid Partner Content
Gilead Sciences: Where's the Value?
Jun 19 / MotleyFool.com - Paid Partner Content
Gilead Sciences Bucks Tradition, Takes 'Low Road' on New Hepatitis C Drug Price
Jun 28 / TheStreet.com - Paid Partner Content
3 Top Big Pharma Stocks to Buy Now
Jun 19 / MotleyFool.com - Paid Partner Content
Regulus Therapeutics Inc. Clinical Hold: Should Investors Be Yellow-Bellied?
Jun 27 / MotleyFool.com - Paid Partner Content
3 Reasons Gilead Sciences Is a Buy
Jun 17 / MotleyFool.com - Paid Partner Content
Better Buy: Merck & Co. Inc. vs. AbbVie
Jun 27 / MotleyFool.com - Paid Partner Content
Wall Street heads for second straight weekly loss
Jun 17 / FT.com - Paid Partner Content
Why Agenus' Stock Has Stumbled in 2016
Jun 27 / MotleyFool.com - Paid Partner Content
Dow 30 Stock Roundup: Microsoft Acquires LinkedIn, Merck to Buy Afferent Pharmaceutic...
Jun 17 / Zacks.com - Paid Partner Content
The 5 Best Healthcare ETFs
Jun 26 / MotleyFool.com - Paid Partner Content
Merck & Co., Inc. Wins This Round of the Immunotherapy Lung-Cancer Battle
Jun 16 / MotleyFool.com - Paid Partner Content
Can Gilead Sciences Rebound in the Second Half of 2016?
Jun 25 / MotleyFool.com - Paid Partner Content
Merck & Co. Inc. Shares Jump On Positive Lung Cancer Treatment Trial Results
Jun 16 / Zacks.com - Paid Partner Content
Why Investors Are Paying a Premium for These 3 Drugmakers
Jun 24 / MotleyFool.com - Paid Partner Content
President raises patient and business hope for cancer treatment
Jun 02 / FT.com - Paid Partner Content
Sanofi's Likely Sweetener for Medivation Panned
Jun 23 / TheStreet.com - Paid Partner Content
Cancer doctors face next drug challenge
Jun 01 / FT.com - Paid Partner Content
Incyte Reports Epacadostat Combination Study Initiation
Jun 23 / Zacks.com - Paid Partner Content